Shared Decision Making in Patients With Lung Cancer

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorSichuan Cancer Hospital and Research Institute

About this trial

The objective of this study is to develop a Decision Aid for Lung Cancer Molecular Testing (DA\_LCMT) and to facilitate shared-decision making in patients who were diagnosed with lung adenocarcinoma by intraoperative frozen pathology about whether to conduct the molecular testing.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial population

Non-random purposive sampling will be used to select key respondents to participate in in-depth interviews. Snowball sampling, where potential participants are asked to identify others who may be willing to participate, as well as convenience sampling, will be utilized. For patients, we will aim for diversity regarding age, sex, education level, and annual household income. For other stakeholders (including thoracic surgeons, nurses, psychoanalysts, hospital administrators, molecular testing company staff, and insurance company staff), the representativeness in region, seniority, position, and attitude toward both molecular testing and SDM will be considered.

Trial design

Design model

Case-crossover

Time perspective

Prospective

Treatments tested in this trial

  • Qualitative interviews

    Other intervention

    We will conduct semi-structured interviews with target patients, patients' representatives and other stakeholders to assess their decisional needs. The cognitive debriefing interview will start afterwards, and participants will answer probing questions asked by interviewers about DA\_LCMT 1.0. Then the field testing interviews will conducted one-on-one structured interviews.

Treatment groups

190 Participants
are divided into 5 treatment groups
Group A: Patients of decision making need assessment1 intervention
Group B: Other stakeholders of decision making need assessment1 intervention
Group C: Participants of cognitive debriefing/alpha tests1 intervention
Group D: Patients of Field testing /β tests1 intervention
Group E: Clinician of Field testing /β tests1 intervention

Trial outcomes

Primary outcomes

1

The DA_LCMT 3.0

The DA\_LCMT 3.0 is the final version in this study which must conform to the International Patient Decision Aid Standards (IPDAS)

Time frame
3 days

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Sichuan Cancer Hospital and Research Institute

Lead sponsor

Jiangyou People's Hospital

Collaborator

Wu Jieping Medical Foundation

Collaborator

Chongqing Medical University

Collaborator

The Third People's Hospital of Chengdu

Collaborator